Clinical Trials Logo

Melanoma (Skin) clinical trials

View clinical trials related to Melanoma (Skin).

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT03311542 No longer available - Clinical trials for Glioblastoma Multiforme

Expanded Access for Pembrolizumab (MK-3475)

Start date: n/a
Phase: N/A
Study type: Expanded Access

This is an expanded access program (EAP) for patient with Melanoma and Glioblastoma who have progressed after prior Protocol therapy including Bevacizumab, Temozolomide ( TMZ ), Ipilimumab, BRAF and MEK inhibitors. The patients whose tumors are EGFR, MET or ALK positive should first receive an EFGR or ALK inhibitor, respectively, prior to treatment with pembrolizumab.

NCT ID: NCT01005537 No longer available - Melanoma (Skin) Clinical Trials

Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma

Start date: June 2009
Phase: N/A
Study type: Expanded Access

RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Biological therapy, such as cellular adoptive immunotherapy using autologous lymphocytes, may stimulate the immune system in different ways and stop tumor cells from growing. Aldesleukin may stimulate the lymphocytes to kill tumor cells. Giving cyclophosphamide together with autologous lymphocytes and aldesleukin may be an effective treatment for metastatic melanoma. PURPOSE: This phase I/II trial is studying the side effects of giving cyclophosphamide together with autologous lymphocytes and aldesleukin and to see how well it works in treating patients with metastatic melanoma.